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Abstract Objective Premature infants have the highest risk of being hospitalized with respiratory
syncytial virus (RSV) infections. Palivizumab is the only licensed agent for RSVhospitaliza-
tion (RSVH) prophylaxis in infants born at < 35 weeks of gestational age (wGA). In 2016,
the ItalianDrugAgency (Agenzia Italianadel Farmaco [AIFA]) has restricted the eligibility for
reimbursement to infants at high risk of RSVH, ruling out palivizumab administration for
infants born at > 29 wGA. The aim of the present study was to compare the incidence of
RSVH in twoconsecutive epidemic seasons (2015–2016vs. 2016–2017), that is, before and
after the new AIFA recommendations on palivizumab eligibility.
Study Design This was a noninterventional retrospective cohort study conducted at
three neonatal intensive care units (NICUs) in northern Italy. Infants born at 29 and 35
wGA between March 15, 2015 and March 14, 2017 were enrolled for this study.
Electronic medical charts were reviewed and parents were interviewed by telephone.
Data were collected on neonatal course during NICU stay, palivizumab administration,
and hospitalizations related to respiratory infections during the 1st year of life,
comparing the infants born in season 1 with season 2.
Results Of 632 eligible infants, data were available for 536 (262 in season 1 and 274 in
season 2). Overall, RSVH occurred 1.9 and 5.1% in infants in seasons 1 and 2,
respectively (odds ratio [OR] ¼ 2.77; 95% confidence interval [CI]: 0.98–7.8,
p ¼ 0.045). When the analysis was limited to patients not exposed to palivizumab,
RSVHs were recorded for 1.8 and 5.9% infants in seasons 1 and 2, respectively
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Respiratory syncytial virus (RSV) is the most common cause
of lower respiratory illness among infants, resulting in
annual epidemics worldwide. RSV infection is a significant
health care issue for infants in the early months of life, and
especially in those born prematurely. Hospitalizations and
outpatient visits for community-acquired RSV infections are
associated with significant health care costs and resource
usage. The management of RSV-related illness has remained
largely unchanged in the last decades, and is mainly suppor-
tive. The monoclonal antibody palivizumab is the only agent
marketed and approved for RSV prophylaxis, but its use is
restricted to high-risk children (preterm-born infants, chil-
drenwith chronic lungdisease [CLD] of prematurity, children
with hemodynamically significant congenital heart disease
[HSCHD], and those with neuromuscular disease).1,2 A
Cochrane’s review published in 2013 concluded that palivi-
zumab is effective in reducing the incidence of RSV-related
hospitalizations (RSVH) for severe lower respiratory tract
infections involving children with chronic lung disease or
congenital heart disease, or infants born preterm. It is worth
noting that the Cochrane’s reviewconsidered all infants born
preterm as a single group, irrespective of their gestational
age at birth.3Guidance for palivizumab prophylaxis from the
American Academy of Pediatrics, updated in 2014, did not
include preterm infants born at > 29 weeks of gestation
(wGA) in the recommendations to receive that treatment,
unless there were comorbidities involved.4
In Italy, palivizumab was administered to all premature
infants born at < 32 wGA and also to those born at 33 to 35
wGA if they had certain additional risk factors up until 2016.
Then the Italian Drug Agency (Agenzia Italiana del Farmaco
[AIFA]) downgraded palivizumab reimbursement to include
only premature infants born at < 29 wGA. The concomitant
updateon thescientific recommendations issuedbythe Italian
Society of Neonatology took a different approach, continuing
to recommend palivizumab administration for infants born
between 29 and 32 wGA.5 While it is hard to establish a
definite gestational age “threshold” distinguishing between
high-risk and low-risk infants, current evidence in the litera-
ture indicates that preterm infants born at 29 to 35wGAare all
at risk of severe RSV-related disease than term-born infants,
particularly in the early months of life.6 Lanari et al demon-
strated that the risk estimates for hospital admissions due to
bronchiolitis doubled for infants born at 33 to 34 wGA
compared with those born at term.7 A recently-published
observational cohort study, the SENTINEL study, investigated
the burden of severe RSV-related disease in infants born at 29
to 35 wGA who were not given palivizumab; it showed that
earlier GAandyounger chronological agewere associatedwith
the highest risk of severe RSV-related disease in terms of
hospitalizations, admission to intensive care units, and need
for mechanical ventilation.8 There is, therefore, a discrepancy
between the scientific recommendations and the rules gov-
erning eligibility for palivizumab reimbursement. The scien-
tific societies have encouraged the production of more data
and further studies to clarify this conflicting issue.
With this perspective,wedesigned a study to compare the
incidence of RSVH among infants born at 29 to 35wGA in the
season before (2015–2016) or after (2016–2017) the intro-
duction in 2016 of the AIFA’s more restricted recommenda-
tions for palivizumab.
Materials and Methods
This retrospective observational cohort studywas conducted
at three neonatal intensive care units (NICUs) in northern
Italy. All Infants born at 29 to 35wGAduring two consecutive
epidemic seasons were identified from birth registries and
health service administrative data.
Season 1 included infants born at 29 to 35 wGA between
March 15, 2015 and March 14, 2016. These infants would
have received palivizumab based on the following criteria:
(1) prematurity < 326/7 wGA and < 12months old; (2) birth
at 33 to 35 wGA and additional risk factors (exposure to
smoke, treatment with surfactant, living with siblings < 10
years old, attendance at daycare), and < 12 months old; (3)
CLD and < 12 months old; (4) CLD and < 24 months old
when medical therapy was required at the start of the
season; (5) HSCHD and < 12 months old; and (6) neuro-
muscular diseases, congenital abnormalities of the airways,
or immune deficiency, and < 12 months old.
Season 2 concerned infants born at 29 to 35 wGA between
March 15, 2016 and March 14, 2017. This group would have
received palivizumab in the case of: (1) prematurity < 296/7
wGA and < 12months old; (2) CLD and < 12months old; (3)
CLDand < 24months oldwhenmedical therapywas required
at the start of the season; (4) CHD and < 12 months old; and
(5) neuromuscular diseases, or congenital abnormalities of the
airways, or immune deficiency, and < 12 months old.
The following information on the patient’s neonatal char-
acteristics and clinical coursewhile at the NICUwas obtained
fromelectronicmedical charts: GA and birthweight, need for
(OR ¼ 3.42; 95% CI: 0.96–12.20, p ¼ 0.045). It is noteworthy that the incidence of
hospital admissions for respiratory viruses other than RSV did not differ between the
two seasons.
Conclusion Restricting eligibility for palivizumab reimbursement led to a significant
increase in RSVH but had no impact on hospitalizations for other respiratory viruses.
Future decisions on palivizumab prescription and coverage rules should be driven by a
careful assessment of the cost-benefit ratio.
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mechanical ventilation, diagnosis of CLD or HSCHD, indica-
tions for palivizumab prophylaxis, number of doses, mode of
administration, and compliance. Infants with major conge-
nital anomalies other than HSCHD were excluded from the
study.
Palivizumab (Synagis, AbbVie Srl, Aprilia, Italy) 15 mg/kg
was administered in five monthly courses over the epidemic
seasons (from late November to late March) according to
existing protocols and guidelines.5 The same timing and
dosage were used for all infants, regardless of their GA and/
or underlying conditions. None of the infants were treated out
of season.
Cases of bronchopulmonary dysplasia (BPD) were identi-
fied from themedical records in compliancewith the criteria
stipulated by the consensus definitions of BPD.9 The HSCHD
was defined as uncorrected, or palliated cyanotic or acya-
notic CHD with pulmonary hypertension (systolic pulmon-
ary arterial pressure > 40 mmHg), or need formedication to
manage congestive heart failure, and the diagnosis was
confirmed by a pediatric cardiologist.10
Parents of eligible infants were interviewed by telephone
through a questionnaire to collect additional information
about the number and age of siblings at home, daycare
attendance, breastfeeding, exposure to smoke, and hospitali-
zations for respiratory infections during the 1st year of life. A
risk factor score was calculated, scoring one point for each of
the following: (1) more than two siblings at home; (2) daycare
attendance; (3) no breastfeeding, or breastfeeding for less than
2 months; (4) parental smoking; and (5) discharge from the
NICU in the epidemic season. When hospital admissions for
respiratory infections were reported, parents were invited to
provide all related medical records. A thorough review of this
clinical documentationwasperformed to checkwhether these
hospitalizations were related to RSV infection or not (as
primary and secondary outcomes, respectively).
RSVHs were defined as symptomatic admissions to hos-
pital for deep or wet chest cough, wheezing, hoarseness,
stridor, or shortness of breath. RSV positivity was confirmed
by enzyme or immunofluorescent assay, polymerase chain
reaction, or a positive viral culture for RSV from nasophar-
yngeal secretions.11
For the purpose of this study, only the first episode of
RSVH in each infant was considered. The infants’ age at the
time of their RSVH, and the need for mechanical ventilation
or admission to the NICU were also recorded.
Informed consent for the collection of the infants’medical
data was obtained from parents shortly after birth and
confirmed at the time of the telephone interview.
Statistical Analysis
The demographic and clinical data examined are reported as
counts (percentages) for categorical variables and mean 
standard deviation (SD) for normally-distributed continuous
variables. Proportions and continuous variables were com-
pared using Fisher’s exact two-tailed test and the t-test, respec-
tively. Specifically, the association between RSVH and season
(classified as a dichotomous variable: season 1/season 2) was
assessed with Fisher’s exact test.
RSVH risk ratios and corresponding 95% confidence inter-
vals (CIs) were calculated to compare between-group cumu-
lative incidences, and odds ratios (ORs) were computed. All
tests were two-tailed, and a p < 0.05 was assumed to
indicate statistical significance. All analyses were run using
the SPSS software, version 13.0 (SPSS Inc, Chicago, IL).
Results
►Fig. 1 shows the patient flow between 2015 and 2017.
A total of 632 eligible infants identified from the birth
registries at the three centers, 314 in season 1 and 318 in
season 2, were considered for this study. Data were unavail-
able for 96patients (52 in season 1 and 44 in season 2) because
parents could not be interviewed or contacted, or refused
consent. The sample included in the final analysis thus con-
sisted of 536 infants (262 in season 1 and 274 in season 2).
►Table 1 shows the baseline characteristics and demo-
graphic features of the infants in the two seasons. There were
no significant differences between the two groups in terms of
mean gestational age, birthweight, multiple pregnancies, need
for mechanical ventilation during NICU stay, proportion of
infants with HSCHD, or risk factor scores. The only difference
concernedtheproportionof infantsdischargedwithadiagnosis
of BPD, which was significantly higher in the second season.
The proportion of infants was not exposed to palivizumab
increased significantly from 63.7% in season 1 to 80.6% in
season2 (p-value < 0.0001). Similarly theproportionof infants
hospitalized for confirmed RSV-related respiratory infections
rose from 5 (1.9%) of 262 infants in season 1 to 14 (5.1%) of 274
infants in season 2 (OR ¼ 2.77; 95% CI: 0.98–7.78; p-value
¼ 0.045). When only the infants not exposed to palivizumab
were considered, a similar increase emerged from 3 (1.8%) of
167 infants in season 1 to 13 (5.9%) of 221 infants in season 2
(OR ¼ 3.42; 95% CI: 0.96–12.20; p-value ¼ 0.044).
Season 2 (2016–2017) 318
patients
632 patients born at 290/7–350/7 wGA
between March 15, 2015 and March 14, 2017
Season 1 (2015–2016) 314
patients
52 excluded because of
 -  parents could not be
      contacted
 -  parents refused consent
Season 1 (2015–2016) 262
patients enrolled
95/262 received
palivizumab
Season 2 (2016–2017) 274
patients enrolled
44 excluded because of
 -   parents could not be
   contacted
 -   parents refused consent
53/274 received
palivizumab
Fig. 1 Study flow chart. wGA, weeks of gestational age.
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In contrast, there was no significant difference between
the two seasons in the incidence of hospital admissions for
low respiratory tract infection caused by respiratory viruses
other than RSV.
In accordancewith AIFA and scientific society recommen-
dations, all infants with BPD in either season were given
palivizumab. Only one episode of RSVH occurred among
these infants, and it happened in season 1. This clearlymeans
that there was no impact on the above-mentioned results
attributable to the increase in the number of BPD patients in
season 2, as previously reported.
It is worth noting that the 14 episodes of RSVH occurring
in season 2 affected infants with gestational ages of 31weeks
(three cases), 32 weeks (two cases), 33 weeks (two cases),
34 weeks (two cases), and 35 weeks (five cases), whereas the
five episodes occurring in season 1 involved infants with
gestational ages of 31 weeks (one case), 33 weeks (three
cases), and 34 weeks (one case).
Discussion
The present study assessed the burden of RSVH for infants
born at 29 to 35 wGA and discharged from three NICUs in
northern Italy during two consecutive seasons in which two
different palivizumab prophylaxis allocation policies were
adopted following changes to AIFA’s reimbursement policies.
It emerged that the overall incidence of RSVH increased
significantly in the season 2, when eligibility for prophylaxis
with palivizumab free of charge was restricted to infants
born < 29 wGA and denied to those with gestational ages
between 29 and 35 weeks.
Our results confirmandreinforcesimilar reports fromother
countries and health care settings. In the U.S.A., Rajah et al
found a significant increase in the number of RSVH involving
infants up to 6 months old born at 29 to 346/7 wGA after the
implementation of the 2014 recommendations of the Amer-
ican Academy of Pediatrics, as well as an increased morbidity
(in terms of the need for oxygen supplementation, admission
to pediatric intensive care units, mechanical ventilation, and
length of hospital stay) in 29 to 34 6/7 wGA in < 3 months old
infants.12 Likewise, in a single-center study from Italy that
retrospectively reviewed the records for children12months
old admitted to hospital for RSV-induced lower respiratory
tract infections from 2014 to 2017, therewas a higher propor-
tion of admissions for infants born < 36 wGA, and a greater
need for high-flow nasal cannula ventilation in the 2016 to
2017 epidemic season (after more restrictive palivizumab
allocation policies had been implemented) than in the pre-
vious two seasons.13 In Italy, the birth rate is approximately
450,000/year, and it is estimated that some 5% of infants are
Table 1 Infant baseline characteristics and hospital admissions for respiratory infections proportions
Season 1
2015–2016
n ¼ 262 (%)
Season 2
2016–2017
n ¼ 274 (%)
OR 95% CI p-Value
Gestational age (days), mean (SD) 229 (10.9) 228 (11.6) – – 0.54
Birth weight (grams), mean (SD) 1,803 (441.4) 1,768 (492.9) – – 0.39
Mechanical ventilation during
NICU stay (at least 24 hours)
101/262 (38.5) 106/274 (38.6) – – 0.98
CLD 0/262 (0) 12/274 (4.4) – – < 0.001
HSCHD 6/262 (2.3) 8/274 (2.92) – – 0.37
Multiple pregnancies 87/262 (33.2) 92/274 (33.6) – – 0.92
Patients not exposed to palivizumab 167/262 (63.7) 221/274 (80.6) – – < 0.001
Risk factor scorea – – 0.85
0 28/262 (10.7) 29/274 (10.6) – – –
1 83/262 (31.7) 95/274 (34.7) – – –
2 91/262 (34.7) 95/274 (34.7) – – –
3 51/262 (19.5) 44/274 (16.1) – – –
4 9/262 (3.4) 11/274 (4.0) – – –
RSVH among all infants 5/262 (1.91) 14/274 (5.11) 2.77 0,98–7.80 0.045
RSVH among infants not exposed to palivizumab 3/167 (1.80) 13/221 (5.88) 3.42 0.96–12.20 0.045
RSVH among infants exposed to palivizumab 2/95 (2.10) 1/53 (1.88) 1.09 0.67–1.35 0.88
Hospitalizations for bronchiolitis unrelated to RSV 11/262 (4.20) 14/274 (5.11) – – 0.63
Abbreviations: CI, confidence interval; CLD, chronic lung disease; HSCHD, haemodynamically significant congenital heart disease; NICU, neonatal
intensive care unit; OR, odds ratio; RSV, respiratory syncytial virus; RSVH, hospitalization due to RSV; SD, standard deviation.
Note: Data are unless otherwise stated as n (%).
aRisk factor score was calculated, scoring one point for each of the following: (1) more than two siblings at home; (2) daycare attendance; (3) no
breastfeeding, or breastfeeding for less than 2 months; (4) parental smoking; and (5) discharge from the NICU in the epidemic season.
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born at between29 and 35wGA, that is, approximately 22,500
newborns. Assuming a 3.2% increase in RSVH, as suggested by
the results of our analysis, we should expect an increase of
approximately 720 admissions in a year in this subgroup of
premature infants. Though a thorough economic analysis goes
beyond the scope of this study, our findings indicate that it is
mandatory to consider the health care costs resulting from
excessively restrictive rules covering the prescription of pali-
vizumab. Our conclusion is consistent with the report from
Zuccotti and Fabiano, who performed an economic impact
analysis on RSV-related hospitalization and clinical examina-
tions for infants < 3 years old, and concluded that extending
the prophylaxis to infants born at 29 to 32 wGA up until they
are 6 months old is a cost-effective strategy.6 Besides there is
the indirect burden of RSV-related infections to consider,
including social costs, parental burden,14 and long-term
respiratory sequelae. It is well known that RSV infection,
especially when severe, is a risk factor for recurrent wheezing,
asthma, and overall lung function impairment. The multi-
center, randomized controlled MAKI trial performed by the
Dutch RSVNeonatal Network showed a 61% relative reduction
in the number of wheezing days during the 1st year of life in
infantsbornat33 to35wGAwhowereexposed topalivizumab
as opposed to placebo.15 Mochizuki et al also documented a
significant reduction in the prevalence of wheezing at 6 years
ofage inagroup treatedwithpalivizumabversusplacebo (15.3
and 31.6%).16 These data point to the real advisability of
preventing severe RSV-related infections in infants (especially
those at high risk) to limit late negative outcomes of early
exposure to this pathogen.
It is worth emphasizing that the restrictions on eligibility
for palivizumab reimbursement in season 2 led to a signifi-
cant increase in RSVH, but had no impact on hospital
admissions for other respiratory viruses. This is important
in that it rules out the possible influence, for instance, of
other environmental conditions relating to respiratory
viruses circulating in the community, or of an overall higher
risk of respiratory disorders in the study population in
season 2, to justify the excess number of RSVH.
Limitations
We acknowledge that our study has some limitations. Due to
the small size of the samples of infants, who experienced an
episode of RSVH, it was impossible to stratify the risk by
gestational age at birth. In addition, data collection was
based on a search for birth data and telephone interviews,
so the study is prone to recall bias. We are, nonetheless,
convinced that a hospital admission is amemorable event for
an infant’s parents and unlikely to be overlooked by the
questionnaire that we administered to parents, whose com-
pliance in answering the interview questions and coming to
the center in the event of hospitalizationwas generally good.
Conclusion
In conclusion, the results of our study confirm previously-
published evidence, and underscore the fact that all preterm-
born infants, regardless of their gestational age, are highly
vulnerable to severe RSV-related infections. In addition, this
study shows that the incidence of RSVH increases signifi-
cantly when eligibility for palivizumab prophylaxis is
restricted. Clinicians and policy-makers should carefully
consider the cost-benefit balance concerning palivizumab
prophylaxis, and be aware that a limited coverage is likely to
bring a surge in RSVH for infants not receiving it.
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